Professional
Added to YB: 2024-08-07
Pitch date: 2024-06-30
NVO [bullish]
Novo Nordisk A/S
-64.26%
current return
Author Info
No bio for this author
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Market Cap
DKK 1.4T
Pitch Price
DKK 140.41
Price Target
N/A
Dividend
3.64%
EV/EBITDA
8.92
P/E
13.70
EV/Sales
4.72
Sector
Pharmaceuticals
Category
growth
Long Equity Portfolio Holding: Novo Nordisk A/S
NVO: Diabetes care leader, 63% sales N. America, 6% China. Revenue: GLP-1 71%, insulin 28%, obesity 24%. Strong brand, innovative R&D. Growth from emerging markets, obesity treatment advances. Competitive edge in global diabetes epidemic. Focus on GLP-1 receptor agonists & insulin.
Read full article (1 min)